While programmed cell death-1 (PD-1) inhibitors, particularly nivolumab, have provided significant progress in the treatment of metastatic NSCLC, only a limited number of patients achieve durable responses [2]. Here, PDCD1 is linked to non-small cell lung carcinoma.